Applied Genetic Technologies (AGTC) Scheduled to Post Earnings on Tuesday

Share on StockTwits

Applied Genetic Technologies (NASDAQ:AGTC) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 12th. Analysts expect Applied Genetic Technologies to post earnings of ($0.58) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Applied Genetic Technologies (NASDAQ:AGTC) last issued its quarterly earnings results on Thursday, September 26th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.04). Applied Genetic Technologies had a negative return on equity of 2.49% and a negative net margin of 4.81%. The business had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.71 million. On average, analysts expect Applied Genetic Technologies to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of Applied Genetic Technologies stock opened at $3.08 on Friday. The business’s fifty day moving average is $3.30 and its two-hundred day moving average is $3.65. The firm has a market cap of $58.85 million, a PE ratio of -28.00 and a beta of 2.58. Applied Genetic Technologies has a fifty-two week low of $2.26 and a fifty-two week high of $7.48.

Several analysts have recently weighed in on the company. Wedbush raised their target price on Applied Genetic Technologies from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Friday, September 27th. Janney Montgomery Scott assumed coverage on Applied Genetic Technologies in a research note on Friday, September 6th. They set a “buy” rating and a $13.00 target price for the company. BMO Capital Markets upgraded Applied Genetic Technologies from a “market perform” rating to an “outperform” rating and raised their target price for the company from $5.00 to $9.00 in a research note on Friday, September 27th. Chardan Capital upgraded Applied Genetic Technologies from a “neutral” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Tuesday, September 3rd. Finally, TheStreet downgraded Applied Genetic Technologies from a “c-” rating to a “d” rating in a research note on Monday, September 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Applied Genetic Technologies has an average rating of “Buy” and a consensus price target of $11.32.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Featured Story: What Does Beta Mean In Stock Selection?

Earnings History for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.